Less than two months after splitting from Illumina, the liquid biopsy maker is refocusing resources as it pursues an FDA submission for the Galleri multi-cancer early detection test.
Read more about this post on BioPharmaDive
Trending
- Confronting Challenges with Wisdom in Life Sciences
- Veteran-Led Psychedelic Fitness Launches Beta Phase in Health-Tech Revolution
- Ono Pharma Collaborates with Congruence Therapeutics to Advance Neurology and Immunology Research
- Legend Biotech Q1 Loss Continues to Challenge Profitability Outlook
- Mpox Case Confirmed in Connecticut Following Travel to Western Europe
- Catalent and Elpida Therapeutics Forge Strategic Late-Phase AAV Production Alliance
- Spring 2026 Highlights: Nevada Silver & Blue Edition
- Celebrating Innovative Human-Centered Technology in Healthcare
Grail to shed 350 workers in restructuring
By Susan Kelly